Table 2. Univariate analysis results for prognostic factors in the derivation set.

Variable		n=235	Overall Survival (months)		P-value (log rank)
			Median	95% CI
Age	<65	211	37	32.4-41.6
	>=65	24	44	27.7-59.3	0.894
Gender	Male	204	37	30.4-43.6
	Female	31	38	30.1-45.9	0.678
Child-Pugh increase	Absent	67	44	28.5-59.5
	+1 point	34	36.2	19.3-53.1
	>=2 points	134	35	26.2-43.8	0.015
HBeAg	Positive	168	36	30.6-41.4
	Negative	67	38	31.5-44.5	0.425
*HBV-DNA level (IU/mL)	<=10 4	156	48.1	40.1-56.1
	>10 4	79	27.5	24.4-30.6	<0.001
BCLC stage	A	65	54.2	43.8-64.6
	B	143	35	28.2-41.8
	C	27	20.8	7.2-34.4	<0.001
AST Increase >25%	Absent	126	38	28.9-47.1
	Present	109	35.6	25.8-45.4	0.202
*AFP (ng/mL)	<200	191	43.3	35.1-51.5
	>=200	44	23.2	17.8-28.6	<0.001
*Cirrhosis	Absent	40	37	15.5-58.5
	Present	195	37.4	31.0-43.8	0.452
*Vascular invasion	Absent	110	51.6	44.2-59.0
	Microvascular invasion	98	31.4	26.2-36.6
	Macrovascular invasion	27	18.3	10.8-25.8	<0.001
Tumor diameter (cm)	<5	96	54.2	41.3-67.1
	>=5	139	31.2	25.3-37.1	<0.001
Tumor number (n)	1	139	43.3	32.8-53.8
	>=2	96	33	26.4-39.6	0.095
Capsule	Complete	93	38.7	26.3-51.1
	Incomplete	142	37	30.0-44.1	0.607
Edmonson-Steiner classification	I/II	144	39.8	29.4-50.2
	III/IV	91	35	27.0-43.0	0.096
lymph nodemetastasis	Absent	228	39.2	31.6-43.7
	Present	7	9.1	0-31.3	0.24
Clamping time	Absent	103	43.5	32.0-55.0
	Present	132	35	30.1-40.0	0.234
Blood transfusion	Absent	210	35.1	29.3-44.6
	Present	25	39.6	25.2-51.8	0.778
change of N/L	Increase	100	35.4	28.8-42.0
	Decrease	135	42.4	31.2-53.6	0.058
*Platelets (10 9/L)	<100	178	34.7	29.5-39.9
	>=100	57	54.2	46.4-62.0	0.041